Phase III Confirmatory Study of 0.0015% DE-085 (Tafluprost) Ophthalmic Solution as Compared to 0.005% Latanoprost Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
TAKAGI, Y. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004, 78, 767-776
MISHIMA, HK. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996, 114, 929-932